Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination and acetylcholine receptor antibody titers in autoimmune myasthenia gravis
DRKS00000360Phase 3
Key facts
- Status
- Terminated
- Start
- Mar 2010
- Countries
- 1
- Sponsor
- KKS Marburg
- Modality
- Vaccines & Immunotherapeutics
- Drugs
- Mutagrip
- Conditions
- influenza
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing Mutagrip influenza vaccine with Placebo (0.9% NaCl) (2 arms). Primary endpoint: Change in acetylcholine receptor antibody titers after influenza vaccination. Started Mar 2010; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Mutagrip influenza vaccine
Participants receive a standard intramuscular injection of Mutagrip influenza vaccine into the deltoid muscle.
Placebo (0.9% NaCl)
Participants receive an intramuscular injection of 0.9% NaCl placebo into the deltoid muscle.
03
Who it enrols
Adults with autoimmune myasthenia gravis and positive acetylcholine receptor antibodies; healthy volunteers are not included.
04
Endpoints
Primary
Change in acetylcholine receptor antibody titers after influenza vaccination
Beyond the preview
Go deeper on DRKS00000360.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000360.